This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) (NCT06768658), a randomized phase 1 study. The primary outcome is Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT06768658 |
| Phase | Phase 1 |
| Condition | Nausea and Vomitting |
| Allocation | Randomized |
| Design model | Crossover |
| Masking | Triple |
| Enrollment | 1 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Takeda |
| Results posted | Yes |
2. Clinical Question
Population
Participants with cyclic vomiting syndrome (CVS). The registry record reports enrollment of 1 participant, who received no treatment.
Intervention
Intermittent single doses of TAK-951, intended to be given by subcutaneous injection. The sequence descriptions specify TAK-951 4 mg.
Comparator
A placebo-matching subcutaneous injection, compared within the planned repeated crossover sequences.
Primary question
How many participants experienced at least one treatment-emergent adverse event (TEAE) during the study, up to end of study (up to 44 weeks)? No endpoint data were reported because the participant received no treatment and no data were evaluated or collected for reporting.
The clinical question was principally about safety and tolerability, rather than a definitive estimate of symptom benefit. The brief summary also describes aims to assess how much TAK-951 participants could receive without side effects, how the drug remains in the blood over time, and whether treatment at home is possible. These are aims, not reported findings.
The registry lists secondary outcomes concerning total response, absence of emesis, nausea, nausea scores, rescue medication timing, and anti-drug antibodies. It does not provide results for those outcomes. The central statistical question therefore remains unanswered: the record cannot estimate the frequency of TEAEs under TAK-951 or compare it with placebo.
3. Trial Design
The registry describes a Phase 1 randomized, triple-masked, placebo-controlled repeated crossover study. Its official title identifies intermittent single doses of TAK-951 for abortive treatment of CVS. Randomization and masking describe the intended study design; they do not establish that a treatment comparison was carried out.
The record gives two intended sequences. Sequence 1 is labelled ABBA and describes placebo and TAK-951 4 mg in the order placebo, TAK-951, TAK-951, placebo. Sequence 2 is labelled BAAB and describes TAK-951 4 mg and placebo in the order TAK-951, placebo, placebo, TAK-951. The arm descriptions are truncated in the registry record, so further details of the periods or procedures are not reported there.
The trial started on 2022-03-02, had a primary completion date of 2023-01-09, and is listed as terminated. Enrollment was 1. The record states that the participant received no treatment and that no data were evaluated or collected for reporting because of concern about the risk of re-identification.
In general, a crossover design exposes a participant to more than one treatment condition, allowing comparisons within the same participant when measurements are available. Sequence assignment can help balance treatment order, but a valid treatment comparison also depends on collecting outcomes across the relevant periods and addressing period or carryover effects where appropriate. Those conditions cannot be assessed in this study because the participant received no treatment and no results were reported. Details of the randomization procedure, masking roles, period timing, washout procedures, and analysis of sequence or period effects are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: The study was terminated by the sponsor due to business reasons, before any participant had been dosed in the study. One participant was screened but not dosed with study drug. No data were evaluated or collected for reporting in this study.
Overall Study
| Stage | Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + Placebo | Sequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mg |
|---|---|---|
| STARTED | 0 | 0 |
| COMPLETED | 0 | 0 |
| NOT COMPLETED | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: This study was terminated early and only enrolled one participant that received no treatment. Due to concerns that the participant would be at risk of being re-identified and received no treatment, no data were evaluated and collected to be reported in this study.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: This study was terminated early and only enrolled one participant that received no treatment. Due to concerns that the participant would be at risk of being re-identified and received no treatment, no data were evaluated and collected to be reported in this study.
| Characteristic | Unit | Sequence 1 (ABBA): Placebo + TAK-951 4 mg + TAK-951 4 mg + Placebo | Sequence 2 (BAAB): TAK-951 4 mg + Placebo + Placebo + TAK-951 4 mg | Total |
|---|---|---|---|---|
| Participants analysed | 0 | 0 | 0 | |
| Sex: Female, Male: Female | participants | — | — | — |
| Sex: Female, Male: Male | participants | — | — | — |
| Ethnicity (NIH/OMB): Hispanic or Latino | participants | — | — | — |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | participants | — | — | — |
| Ethnicity (NIH/OMB): Unknown or Not Reported | participants | — | — | — |
| Race (NIH/OMB): American Indian or Alaska Native | participants | — | — | — |
| Race (NIH/OMB): Asian | participants | — | — | — |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | participants | — | — | — |
| Race (NIH/OMB): Black or African American | participants | — | — | — |
| Race (NIH/OMB): White | participants | — | — | — |
| Race (NIH/OMB): More than one race | participants | — | — | — |
| Race (NIH/OMB): Unknown or Not Reported | participants | — | — | — |
| Region of Enrollment: United States | participants | — | — | — |
6. Primary Endpoint
The registry lists the primary outcome as Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE), measured over Up to end of study (up to 44 weeks).
| Element | Registry entry |
|---|---|
| Result type | N/A |
| Measure of spread | not applicable |
| Unit | not stated |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is the number of participants who experience at least one treatment-emergent adverse event (TEAE), with a timeframe of up to end of study (up to 44 weeks). A TEAE is defined in the registry as an adverse event whose onset occurs after receiving study drug. An adverse event is an untoward medical occurrence during a clinical investigation; the definition does not require a causal relationship with treatment. It can include an unfavorable sign, symptom, or disease temporally associated with drug use, whether or not considered related.
In general, a safety endpoint of this kind is used to describe how often participants have events after exposure, rather than to establish that the study drug caused each event. Counting participants with at least one event gives a participant-level summary: repeated events in the same participant do not become separate participants in that count. Interpretation still depends on knowing who was exposed, the follow-up period, and the event ascertainment process.
Those data are unavailable for this study. The record says the enrolled participant received no treatment, and that no data were evaluated or collected for reporting. Consequently, the endpoint cannot characterize adverse events after TAK-951 or support a comparison with placebo. The reason for choosing this endpoint beyond its role as a safety measure is not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record does not contain an evaluable treatment result. It reports enrollment of 1 participant, but also states that the participant received no treatment and that no study data were evaluated or collected for reporting. The primary endpoint, which requires observation after study drug exposure, therefore has no reported outcome value. There is no reported estimate of the number or proportion of participants with a TEAE under TAK-951 or placebo.
The adverse-event listing gives 0 participants at risk and 0 affected for both Placebo and TAK-951 4 mg, with 0 deaths. These entries must be read alongside the record’s explanation that the participant received no treatment and no data were collected or evaluated for reporting. They do not establish that exposed participants had no adverse events, and they cannot be used as evidence that either treatment condition was free of risk. In particular, a zero at-risk count is not an observed safety rate among treated participants.
No results are reported for the 9 listed secondary outcomes, which include measures related to response, emesis, nausea, rescue medication, and anti-drug antibodies. The registry record lists 0 analyses. There are no treatment-effect estimates, confidence intervals, or hypothesis-test results to interpret. No treatment difference, precision estimate, or statistical significance can be inferred from the available record.
In general, estimates from a randomized comparison describe outcomes observed under the assigned conditions, while confidence intervals convey the range of values compatible with the data and analysis assumptions. Neither can resolve the absence of outcome observations. The planned crossover structure does not change this: within-participant comparisons require measured outcomes under the treatment conditions. Since no treatment was received, the record cannot provide such a comparison.
The record identifies early termination and concern about possible re-identification as the reason no data were evaluated and collected for reporting. It does not report a clinical result for TAK-951, nor does it answer whether the intended safety, tolerability, pharmacokinetic, home-administration, or symptom-response aims were met. The statistical interpretation is therefore limited to the fact that the planned study did not produce reportable outcome data.
9. Statistical Methods Explained
Statistical interpretation starts by distinguishing the planned design from the data actually available. This registry describes randomized treatment sequences and a primary safety endpoint, but it also states that the participant received no treatment and that no data were evaluated or collected for reporting. A design can specify how a comparison would have been organized; it cannot supply outcome information that was never collected.
What does the primary endpoint count?
The endpoint counts participants with at least one TEAE. In general, this is a binary participant-level outcome: each participant either has at least one qualifying event during the defined follow-up or does not. A group summary could ordinarily report the count and the number of exposed participants, and an analysis might compare the event frequency between treatment conditions. Neither a count among treated participants nor a meaningful denominator for such a comparison is available.
The definition matters. A TEAE is based on onset after study drug, while an adverse event need not be judged caused by the drug. That distinction separates timing from causality. Even when events are collected, an observed event after treatment does not by itself prove that treatment caused it; clinical assessment and a suitable comparison are needed to understand attribution. In this record, there is no exposure or reported event dataset on which to make either assessment.
What does crossover design require?
General statistical context: in a crossover study, a participant may contribute measurements under more than one treatment condition. Such designs can control for stable differences between participants because comparisons can be made within the same person. They also require outcomes to be observed in the relevant periods. Treatment order, period effects, and carryover can affect interpretation, so the analysis plan should address them where relevant. The registry describes ABBA and BAAB sequences, but does not report treatment-period outcome data or an analysis accounting for these design features.
Randomization is intended to reduce systematic differences in assignment, and masking is intended to reduce influence of treatment knowledge on care or assessment. Here, the registry identifies randomization and triple masking but does not report the roles that were masked or procedural details. More importantly, neither randomization nor masking creates a treatment contrast when the participant received no treatment.
Can uncertainty be quantified?
General statistical context: a confidence interval expresses uncertainty around an estimate under a specified statistical model. For an event frequency, its width depends in part on the amount of relevant outcome information and the number of exposed participants. A p-value, when calculated, addresses compatibility of data with a statistical null model; it does not measure clinical importance or establish causation. This record contains no reported estimates, confidence intervals, or p-values for the primary or secondary outcomes. No precision or significance conclusion can therefore be drawn.
The registry describes a planning-illustration framework using a two-sided significance level of 0.05, equal allocation, and a normal approximation. It also says the illustration is based on a fraction of an observed effect. This is not a reported trial analysis or a justification for the original enrollment target. Because no observed effect is available, the record cannot support an observed-effect-based planning estimate. Any sample-size illustration is planning information, not observed power and not a result of this study.
Why can’t the listed zeros be read as a safety finding?
The adverse-event summary lists 0 at risk and 0 affected for each treatment group. General statistical context: an event frequency requires both observed events and an appropriate exposed population. A zero event count among participants known to have received treatment can be informative only with its denominator and observation context; a zero at-risk count does not describe safety among treated participants. Since the record states that no treatment was received, these entries cannot be interpreted as event-free treatment exposure.
The registry gives no inferential analysis, no estimates of treatment effect, and no reported analysis population beyond the statement about enrollment and lack of treatment. The statistical methods used or intended for a completed comparison are not reported in the registry record. This leaves no basis to reconstruct an adjusted or unadjusted treatment effect, uncertainty interval, or inferential test.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 9 secondary outcomes in addition to the primary safety endpoint. These include total response, absence of emesis, absence of significant nausea, nausea visual rating scale scores, and anti-drug antibodies. Multiple outcomes can create a multiplicity issue when several statistical tests are conducted: in general, the chance of at least one false-positive finding can increase as the number of tests grows. Methods such as prespecifying a hierarchy or adjusting significance thresholds can address that issue, but the registry record does not report a multiplicity strategy.
The record lists 0 analyses and reports no outcome results. As a result, there are no reported tests or estimates to assess for multiplicity, and no adjustment can be inferred. The statistical analysis plan, including any approach to primary and secondary outcome testing, is not reported in the registry record.
Missing data are not described as an ordinary pattern of incomplete outcome collection. The record says the participant received no treatment and no data were evaluated or collected for reporting, citing concern about the risk of re-identification. It does not report imputation, a missing-data model, sensitivity analyses, or rules for handling unavailable observations. Since outcomes were not reported, an assumption about the reason or statistical handling of missing values would be speculative.
The analysis populations are also not reported in detail. The record does not define an intention-to-treat, safety, pharmacokinetic, or per-protocol population for analysis. Although enrollment is stated, treatment exposure and outcome evaluation are absent, so no population-based treatment estimate can be described. These omissions prevent evaluation of how a completed trial might have handled multiplicity, missingness, and analysis-set membership.
11. What the Result Does, and Does Not, Mean
The registry record documents a study that planned a randomized, triple-masked, repeated crossover evaluation of TAK-951 and placebo in CVS. It also documents that the study was terminated early, enrollment was 1, the participant received no treatment, and no data were evaluated or collected for reporting. These registry entries describe what happened to the study and explain why it supplies no treatment outcome estimate.
The record does not show that TAK-951 reduced vomiting or nausea, nor does it show that it failed to do so. It provides no reported symptom-response results, no pharmacokinetic findings, and no evidence about whether home administration was feasible. Likewise, it cannot establish the presence or absence of TEAEs following TAK-951 or placebo exposure. Those conclusions would require observations that are not present in the registry record.
In general, lack of a reportable result is different from a finding of no effect. A study with no outcome observations cannot demonstrate equivalence, rule out an effect, or establish safety. The absence of treatment exposure is also different from observing treatment exposure without an adverse event. The listed 0 at-risk and affected counts do not change these distinctions.
The registry’s stated concern about possible re-identification explains why data were not evaluated and collected for reporting; it does not provide a statistical estimate. The appropriate interpretation is narrow: this record describes the intended study design and its early termination, but it does not answer the clinical or statistical questions the trial was designed to examine.
12. Why This Trial Matters Statistically
This record is statistically important because it illustrates the difference between a registered design and an interpretable comparison. Randomization, masking, a crossover sequence, and a clearly described safety endpoint can define a rigorous plan, but evidence still depends on collected outcomes and treatment exposure. Without those, no estimate of benefit, harm, or uncertainty can be derived.
The crossover design makes the absence of data especially consequential. Its intended advantage is comparison within the same participant across treatment conditions. That advantage exists only when outcomes are observed under those conditions. The registry’s ABBA and BAAB sequence labels do not themselves constitute evidence about the relative performance of TAK-951 and placebo.
The record also demonstrates why denominators matter in safety summaries. A zero at-risk count is not a safety rate, and zero affected participants in that listing cannot be treated as an observed absence of adverse events after exposure. Clear reporting of treatment exposure and outcome availability is essential to interpreting event counts.
Finally, the entry makes an important boundary visible: a study can have a prespecified primary endpoint and several secondary outcomes while still producing no reportable results. The record does not give a statistical analysis plan, multiplicity method, or completed analysis. Recognizing these limits prevents a planned endpoint or a zero-valued listing from being mistaken for a clinical finding.
13. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The principal limitation is that the participant received no treatment and the registry states that no study data were evaluated or collected for reporting. This leaves no outcome observations for the primary safety endpoint or the listed secondary outcomes. The early termination means the intended crossover comparison was not reported as conducted.
Enrollment was 1, and the registry cites concern that the participant could be re-identified as the reason data were not evaluated and collected for reporting. The entry therefore provides no participant-level outcome detail and no treatment-exposure information. Its adverse-event listing has 0 participants at risk in both treatment groups, so it cannot be interpreted as a comparison of event risks among exposed participants.
Additional design and analysis details are not reported in the registry record, including the randomization process, the roles covered by triple masking, period and washout procedures, outcome assessment procedures, and a statistical analysis plan. The record does not specify analysis populations, methods for missing data, or a multiplicity strategy. The arm descriptions are truncated, limiting the detail available about the intended sequences.
The available entry cannot support assessment of treatment effects, precision, statistical significance, or safety after exposure. It also cannot establish whether the study’s pharmacokinetic or home-administration aims were addressed. These are limits of the reported record, not evidence for or against TAK-951.
14. Related Tutorials
15. Related Statistical Calculators
16. Sources
- ClinicalTrials.gov: A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS) — NCT06768658.
- Registry record last updated 2025-07-02; status last verified 2025-06.
- Results first posted 2025-02-05.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
17. Record Summary
The registry record concerns NCT06768658, titled A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS). It describes a Phase 1 randomized, triple-masked, placebo-controlled repeated crossover study of intermittent subcutaneous TAK-951, including TAK-951 4 mg and placebo sequences.
The study is listed as terminated. Its start date is 2022-03-02 and its primary completion date is 2023-01-09. Enrollment was 1. The record states that the participant received no treatment and that no data were evaluated or collected for reporting because of concern about possible re-identification.
The primary endpoint was the number of participants with at least one TEAE, with a timeframe of up to end of study (up to 44 weeks). The registry lists 9 secondary outcomes and 0 analyses. No treatment-effect estimates or outcome results are reported, so the clinical and statistical questions remain unanswered by this record.